2023
Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects
Zhong H, Zhu J, Liu S, Ghoneim D, Surendran P, Liu T, Fahle S, Butterworth A, Alam A, Deng H, Yu H, Wu C, Wu L. Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects. Human Molecular Genetics 2023, 32: 3181-3193. PMID: 37622920, PMCID: PMC10630250, DOI: 10.1093/hmg/ddad139.Peer-Reviewed Original ResearchConceptsPCa riskProstate cancerHuge public health burdenEtiology of PCaBlood protein biomarkersConventional epidemiologic studiesProstate cancer riskPublic health burdenConventional observational studiesCancer Genome AtlasPCa patientsHealth burdenProtein biomarker candidatesObservational studyEpidemiologic studiesCancer riskTherapeutic strategiesCancer-related pathwaysSignificant associationBiomarker candidatesGenome AtlasProtein levelsDrug repurposingRiskPositive association
2008
Adipokine genes and prostate cancer risk
Moore SC, Leitzmann MF, Albanes D, Weinstein SJ, Snyder K, Virtamo J, Ahn J, Mayne ST, Yu H, Peters U, Gunter MJ. Adipokine genes and prostate cancer risk. International Journal Of Cancer 2008, 124: 869-876. PMID: 19035456, PMCID: PMC2879625, DOI: 10.1002/ijc.24043.Peer-Reviewed Original ResearchConceptsProstate cancer riskProstate cancerCancer riskOdds ratioIGF-1Prostate carcinogenesisADIPOQ geneBaseline blood drawCase-control studyAdipocyte-derived cytokineIGFBP-3Serum insulinLEP geneBlood drawFinnish menIntervention groupLarge cohortGG genotypeRelative oddsAdipokine genesAA genotypeCancerVariant allelesA alleleLogistic regression
2007
Insulin Resistance–Related Gene Polymorphisms and Risk of Prostate Cancer
Moore SC, Leitzmann MF, Weinstein SJ, Snyder K, Albanes D, Virtamo J, Graubard BI, Mayne ST, Yu H, Peters U, Gunter MJ. Insulin Resistance–Related Gene Polymorphisms and Risk of Prostate Cancer. Cancer Epidemiology Biomarkers & Prevention 2007, 16: 1315-1317. PMID: 17548707, DOI: 10.1158/1055-9965.epi-07-0191.Peer-Reviewed Original Research
2003
Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States)
Li L, Yu H, Schumacher F, Casey G, Witte J. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes & Control 2003, 14: 721-726. PMID: 14674736, DOI: 10.1023/a:1026383824791.Peer-Reviewed Original ResearchConceptsIGFBP-3 molar ratioInsulin-like growth factorIGFBP-3Prostate cancerHigher IGFOdds ratioSibling-matched case-control studySerum insulin-like growth factorInsulin-like growth factor IProtein 3Growth factorIGFBP-3 associationSerum IGF levelsEffects of IGFConfidence intervalsImportant risk factorCase-control studyConditional logistic regressionGrowth factor IProstatic epithelial cellsAdvanced diseaseSerum IGFIGF levelsAggressive diseaseRisk factors
2001
Insulin-like growth factor-I and prostate cancer: a meta-analysis
Shi R, Berkel H, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. British Journal Of Cancer 2001, 85: 991-996. PMID: 11592771, PMCID: PMC2375097, DOI: 10.1054/bjoc.2001.1961.Peer-Reviewed Original ResearchConceptsHedges's standardized mean differenceLevels of IGFProstate cancer patientsStandardized mean differenceIGFBP-3Prostate cancerHigher IGFCancer patientsInsulin-like growth factorIGF-binding proteinsEffects of IGFCase-control studyLow IGFMEDLINE searchIGFMean differenceGrowth factorCancerPatientsStandard protocolRiskLevelsSequence Analysis of the Human Kallikrein Gene Locus Identifies a Unique Polymorphic Minisatellite Element
Yousef G, Bharaj B, Yu H, Poulopoulos J, Diamandis E. Sequence Analysis of the Human Kallikrein Gene Locus Identifies a Unique Polymorphic Minisatellite Element. Biochemical And Biophysical Research Communications 2001, 285: 1321-1329. PMID: 11478802, DOI: 10.1006/bbrc.2001.5321.Peer-Reviewed Original ResearchConceptsHuman kallikrein gene locusKallikrein gene locusRepeat elementsGene locusLinkage analysisDNA fingerprintingDifferent repeat elementsEnhancers of genesGenomic areasRepetitive sequencesKallikrein locusUntranslated regionChromosome 19q13.4Sequence analysisChromosome 19q13Different allelesMinisatellitesLociDNA strandsSerine proteasesKallikrein geneGenesLevels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence
Yu H, Nicar M, Shi R, Berkel H, Nam R, Trachtenberg J, Diamandis E. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 2001, 57: 471-475. PMID: 11248622, DOI: 10.1016/s0090-4295(00)01003-7.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCase-Control StudiesDisease ProgressionEnzyme-Linked Immunosorbent AssayHumansInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualProstate-Specific AntigenProstatic NeoplasmsConceptsPostoperative serum samplesInsulin-like growth factor IIGFBP-3IGFBP-2Growth factor IProstate cancerSerum levelsSerum samplesFactor IIGFBP-2 levelsIGFBP-3 levelsIGF-I levelsGroup of patientsLow serum levelsProstate cancer patientsProstate cancer recurrenceProtein 2Recurrent diseaseDisease recurrenceMedian timePrognostic valueCancer patientsRadical prostatectomyCancer recurrenceSerum collection
2000
Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up
Vassilikos E, Yu H, Trachtenberg J, Nam R, Narod S, Bromberg I, Diamandis E. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clinical Biochemistry 2000, 33: 115-123. PMID: 10751589, DOI: 10.1016/s0009-9120(99)00099-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedDisease-Free SurvivalFluorescent Antibody TechniqueFollow-Up StudiesHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingProportional Hazards ModelsProstatectomyProstate-Specific AntigenProstatic NeoplasmsRecurrenceRegression AnalysisReproducibility of ResultsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsProstate cancer patientsRadical prostatectomySerum PSACancer patientsPSA assaysUltrasensitive prostate specific antigenPre-operative PSAGroup of patientsSerial serum samplesEarly therapeutic interventionSeminal vesicle invasionSurgical margin positivityProstate-specific antigenRegular PSAUltrasensitive PSAPSA increaseMargin positivityClinical stageGleason scorePrognostic indicatorCapsular invasionTissue involvementTumor volumePatientsFast relapseComparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy
Scorilas A, Yu H, Soosaipillai A, Gregorakis A, Diamandis E. Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. Clinica Chimica Acta 2000, 292: 127-138. PMID: 10686282, DOI: 10.1016/s0009-8981(99)00211-9.Peer-Reviewed Original ResearchConceptsPercent free PSAProstate cancer patientsFree PSAProstate cancerCancer patientsRadical prostatectomyPercent free prostate-specific antigen levelsCancer aggressivenessFree prostate specific antigen levelsProstate-specific antigen levelProstate cancer screening programsAge-matched menCancer screening programsRecurrent prostate cancerBenign prostatic hyperplasiaProstate cancer aggressivenessAntigen levelsTotal PSAGleason scoreHealthy menProstatic hyperplasiaProstatic diseaseScreening programPatientsPathological indicators
1999
Insulin-like growth factors and cancer.
Yu H, Berkel H. Insulin-like growth factors and cancer. Journal Of The Louisiana State Medical Society 1999, 151: 218-23. PMID: 10234899.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorIGF binding proteinIGF-1Growth hormoneIGF familyInvolvement of IGFsEffects of IGFActions of IGFsGrowth factorGH replacement therapyCancer cellsIGF-1 receptorLong-term safetyAnti-proliferative effectsAging-related diseasesProgression of cancerTreatment warrantsReplacement therapyVitamin DCancer preventionIGF-1RIGF-2Epidemiologic studiesWild-type p53 proteinCancer etiology
1997
Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l
Yu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918. PMID: 9072598, DOI: 10.1016/s0022-5347(01)65082-1.Peer-Reviewed Original ResearchMeSH KeywordsFollow-Up StudiesHumansLogistic ModelsMaleMultivariate AnalysisNeoplasm Recurrence, LocalProstatectomyProstate-Specific AntigenProstatic NeoplasmsConceptsProstate-specific antigenPositive surgical marginsPreoperative prostate-specific antigenSerum prostate-specific antigenSerial serum samplesBiochemical relapseSurgical marginsClinicopathological featuresRadical prostatectomyTumor volumeLogistic regression modelsPSA changeGreater preoperative prostate specific antigenPostoperative serum prostate-specific antigenHigher preoperative prostate-specific antigenPostoperative prostate-specific antigenUnconditional logistic regression modelsSerum samplesProstate-specific antigen monitoringSerum PSA changesSubset of patientsUnivariate logistic regression modelYear of surgeryLength of followupConventional prostate specific antigen
1996
Ultrasensitive prostate-specific antigen assays and their clinical application.
Diamandis E, Yu H, Melegos D. Ultrasensitive prostate-specific antigen assays and their clinical application. Clinical Chemistry 1996, 42: 853-857. PMID: 8665675, DOI: 10.1093/clinchem/42.6.853.Peer-Reviewed Original ResearchUltrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers.
Ferguson R, Yu H, Kalyvas M, Zammit S, Diamandis E. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clinical Chemistry 1996, 42: 675-684. PMID: 8653891, DOI: 10.1093/clinchem/42.5.675.Peer-Reviewed Original ResearchConceptsTime-resolved immunofluorometric assayProstate-specific antigenL PSAPotential applicationsUltrasensitive time-resolved immunofluorometric assayUltrasensitive detectionPSA immunoreactivityImmunofluorometric assayWide dynamic rangeFree prostate-specific antigenPostradical prostatectomy patientsEstrogen receptor positivityUltrasensitive PSA assaysDynamic rangePSA changeReceptor positivityProstatectomy patientsProstate cancerBreast cancerPSA assaysHook effectLow analytical limitsSignificant associationMonoclonal antibodiesSerum samplesAssay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screening.
Hoffman B, Yu H, Diamandis E. Assay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screening. Clinical Chemistry 1996, 42: 536-544. PMID: 8605670, DOI: 10.1093/clinchem/42.4.536.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate cancerOccult prostate cancerWhole bloodWhole blood concentrationsExtracts of bloodFilter paper procedureMicrograms/L.Cancer screeningPSA recoverySy/xBloodPlasma fractionConcentration of PSARegression analysisCancerAntigenCentralized laboratoriesMicroL of bufferMicroLFilter paperPaper discsHematocritRecoveryMonthsRe: The Clinical Usefulness of Prostate Specific Antigen: Update 1994
Diamandis E, Yu H. Re: The Clinical Usefulness of Prostate Specific Antigen: Update 1994. Journal Of Urology 1996, 155: 294. PMID: 7490867, DOI: 10.1016/s0022-5347(01)66636-9.Peer-Reviewed Original ResearchDoes prostate cancer start at puberty?
Diamandis E, Yu H. Does prostate cancer start at puberty? Journal Of Clinical Laboratory Analysis 1996, 10: 468-469. PMID: 8951622, DOI: 10.1002/(sici)1098-2825(1996)10:6<468::aid-jcla27>3.0.co;2-u.Peer-Reviewed Original Research
1995
Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique
Zarghami N, Yu H, Diamandis E, Sutherland D. Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. Clinical Biochemistry 1995, 28: 243-253. PMID: 7554242, DOI: 10.1016/0009-9120(95)00010-7.Peer-Reviewed Original ResearchConceptsCK-BB levelsBreast tumor cytosolsCreatine kinase BBCK-BBProstate cancerTumor cytosolsCancer patientsEstrogen sensitivityHealthy subjectsSerum CK-BB levelsActive prostate cancerSensitive immunofluorometric procedurePost-radical prostatectomyProstate cancer patientsSerum CK-BBCK-BB isoenzymeSteroid hormone receptorsSerum PSAProgesterone receptorRadical prostatectomyBreast cancerMale volunteersHealthy volunteersPatientsBreast tumorsUltrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy.
Yu H, Diamandis E, Prestigiacomo A, Stamey T. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clinical Chemistry 1995, 41: 430-434. PMID: 7533672, DOI: 10.1093/clinchem/41.3.430.Peer-Reviewed Original ResearchMeSH KeywordsFluoroimmunoassayHumansMaleMicrochemistryNeoplasm Recurrence, LocalProstatectomyProstate-Specific AntigenProstatic NeoplasmsConceptsTumor-doubling timeProstate-specific antigenProstate cancer relapseRelapse-free periodRadical prostatectomyPSA assaysCancer relapseUltrasensitive prostate specific antigenProstate cancer patientsUltrasensitive assayExponential tumor growthPSA changeCancer patientsPatientsProstatectomyTumor growthEarly detectionRelapseAntigenAssaysBasis of criteriaDaysCystoprostatectomyPostsurgerySurgery
1993
Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies.
Yu H, Diamandis E. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clinical Chemistry 1993, 39: 2108-2114. PMID: 7691442, DOI: 10.1093/clinchem/39.10.2108.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlkaline PhosphataseAntibodies, MonoclonalChromatography, High Pressure LiquidEdetic AcidFemaleFluoroimmunoassayHumansMaleMiddle AgedNeoplasm Recurrence, LocalProstatectomyProstate-Specific AntigenProstatic NeoplasmsQuality ControlReference ValuesSensitivity and SpecificityTerbiumConceptsL PSAPolyclonal detection antibodyUltrasensitive time-resolved immunofluorometric assaySensitive prostate specific antigenPSA antibodyDetection antibodyTime-resolved fluorometryTime-resolved immunofluorometric assayUltrasensitive methodProstate-specific antigenMicrotiter wellsImmunofluorometric assayClinical applicationStreptavidinExtreme sensitivityAssays